These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 32986673)

  • 1. Relationship Between PET-Assessed Amyloid Burden and Visual and Verbal Episodic Memory Performance in Elderly Subjects.
    Squarzoni P; Faria DP; Yassuda MS; Porto FHG; Coutinho AM; Costa NAD; Nitrini R; Forlenza OV; Duran FLS; Brucki SMD; Buchpiguel CA; Busatto GF
    J Alzheimers Dis; 2020; 78(1):229-244. PubMed ID: 32986673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hippocampal subregional volume changes in elders classified using positron emission tomography-based Alzheimer's biomarkers of β-amyloid deposition and neurodegeneration.
    Busatto Filho G; Duran FLS; Squarzoni P; Coutinho AMN; Rosa PGP; Torralbo L; Pachi CGDF; da Costa NA; Porto FHG; Carvalho CL; Brucki SMD; Nitrini R; Forlenza OV; Leite CDC; Buchpiguel CA; de Paula Faria D
    J Neurosci Res; 2021 Feb; 99(2):481-501. PubMed ID: 33073383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The aging brain and cognition: contribution of vascular injury and aβ to mild cognitive dysfunction.
    Marchant NL; Reed BR; Sanossian N; Madison CM; Kriger S; Dhada R; Mack WJ; DeCarli C; Weiner MW; Mungas DM; Chui HC; Jagust WJ
    JAMA Neurol; 2013 Apr; 70(4):488-95. PubMed ID: 23400560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential patterns of regional cerebral hypometabolism according to the level of cerebral amyloid deposition in patients with amnestic mild cognitive impairment.
    Jeon SY; Yi D; Byun MS; Choi HJ; Kim HJ; Lee JH; Baek H; Choe YM; Lee Y; Woo JI; Lee DY
    Neurosci Lett; 2016 Oct; 632():104-8. PubMed ID: 27574728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- positive vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer's Disease and Amnestic Mild Cognitive Impairment.
    Wang Y; Lou F; Li Y; Liu F; Wang Y; Cai L; Gordon ML; Zhang Y; Zhang N
    Curr Alzheimer Res; 2021; 18(6):523-532. PubMed ID: 34598664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly.
    Wirth M; Oh H; Mormino EC; Markley C; Landau SM; Jagust WJ
    Alzheimers Dement; 2013 Nov; 9(6):687-698.e1. PubMed ID: 23474040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease.
    Bunai T; Kakimoto A; Yoshikawa E; Terada T; Ouchi Y
    J Alzheimers Dis; 2019; 69(2):529-538. PubMed ID: 31104023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
    Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
    Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals.
    Wirth M; Madison CM; Rabinovici GD; Oh H; Landau SM; Jagust WJ
    J Neurosci; 2013 Mar; 33(13):5553-63. PubMed ID: 23536070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
    Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
    J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between biomarkers in aging and dementia.
    Jagust WJ; Landau SM; Shaw LM; Trojanowski JQ; Koeppe RA; Reiman EM; Foster NL; Petersen RC; Weiner MW; Price JC; Mathis CA;
    Neurology; 2009 Oct; 73(15):1193-9. PubMed ID: 19822868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease.
    Tanner JA; Iaccarino L; Edwards L; Asken BM; Gorno-Tempini ML; Kramer JH; Pham J; Perry DC; Possin K; Malpetti M; Mellinger T; Miller BL; Miller Z; Mundada NS; Rosen HJ; Soleimani-Meigooni DN; Strom A; La Joie R; Rabinovici GD
    Brain; 2022 Dec; 145(12):4489-4505. PubMed ID: 35762829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deficits in short-term memory binding are detectable in individuals with brain amyloid deposition in the absence of overt neurodegeneration in the Alzheimer's disease continuum.
    Cecchini MA; Yassuda MS; Squarzoni P; Coutinho AM; de Paula Faria D; Duran FLS; Costa NAD; Porto FHG; Nitrini R; Forlenza OV; Brucki SMD; Buchpiguel CA; Parra MA; Busatto GF
    Brain Cogn; 2021 Aug; 152():105749. PubMed ID: 34022637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals.
    Perrotin A; Mormino EC; Madison CM; Hayenga AO; Jagust WJ
    Arch Neurol; 2012 Feb; 69(2):223-9. PubMed ID: 22332189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcortical and Cortical Regions of Amyloid-β Pathology Measured by 11C-PiB PET Are Differentially Associated with Cognitive Functions and Stages of Disease in Memory Clinic Patients.
    Almkvist O; Brüggen K; Nordberg A
    J Alzheimers Dis; 2021; 81(4):1613-1624. PubMed ID: 33967046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people.
    Wirth M; Villeneuve S; Haase CM; Madison CM; Oh H; Landau SM; Rabinovici GD; Jagust WJ
    JAMA Neurol; 2013 Dec; 70(12):1512-9. PubMed ID: 24166579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
    Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
    J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.